INTRODUCTION {#s1}
============

As cancer chemotherapeutics improve, the need for companion diagnostics to monitor the effects of such therapeutics becomes progressively more important.\[[@R1]\] The ideal marker would be one that can be simply assessed without the need for repeat biopsies or exposure to irradiation, is absolutely specific for the presence of the tumor (to avoid false positives), is sensitive for the presence of disease, and is cost-effective.\[[@R2]\] Among the many new biomarkers being developed, those employing free, circulating somatically mutated DNA sequences in the plasma are particularly attractive because they can in theory meet all these criteria.\[[@R3], [@R4]\] In particular, mutations are exquisitely tumor-specific because they are not found in any collection of normal cells in the patient, and thereby have advantages over markers that are simply associated with tumors, such as CEA or PSA.\[[@R5]\]

Circulating mutant DNA has been found in a variety of solid tumors and initial studies have shown them to provide sensitivity and specificity comparable or superior to conventional disease indicators.\[[@R6]\] In liquid tumors such as leukemias, consistently fused genes like BCR-ABL provide extraordinarily useful markers for following patients during their treatment.\[[@R7]\] In leukemia patients, rearrangements can be accessed in the blood or bone marrow by virtue of the fact that any residual cancer cells will reside in these compartments.\[[@R8]\] In tumors such as lymphomas, however, circulating cells are not consistently found in patients\' blood or marrow. Based on the above-cited results on solid tumors, however, we hypothesized that somatically rearranged DNA templates from lymphomas might be found in the cell-free fraction of blood, i.e., the plasma.

To test this hypothesis, and to develop a generally applicable tool for companion diagnostics of B-cell lymphomas, it was first necessary to identify aberrant DNA sequences that could be identified in lymphoma patients. Though no specific point mutations or oncogene rearrangements are found in lymphomas in general, virtually all lymphomas harbor rearrangements in their immunoglobulin (Ig) genes.\[[@R9]\] Clever assays that reveal such rearrangements have been described, particularly those employing multiplex PCR to identify clonal rearrangements upon electrophoresis through an increase in the signal of a fragment "spike" representing the rearrangement.\[[@R10]\] Though such assays are clinically useful in many situations, the "spikes" representing clonal rearrangements can be difficult to detect, either because of inefficient primer annealing to the hypermutated sequences in rearranged Ig genes. More importantly, such assays cannot provide optimal sensitivity, as the tumor-specific spikes are overlaid on a background of normal Ig rearrangements. The tumor-specific rearrangements can therefore only be observed if their abundance is significantly greater than the aggregate level of rearrangements from normal B cells. Nonetheless, the appearance of such spikes in plasma correlates with the presence of lymphoma and persistence of such spikes following chemotherapy seems to portend a poor prognosis. To enhance the specificity of this plasma-based approach, we set out to use a capture-and-sequence method to more specifically identify rearrangements of IgH genes at the sequence level then to use this information to detect the same rearrangements in the plasma of NHL patients.

RESULTS {#s2}
=======

Strategy {#s2_1}
--------

We chose to identify the rearrangements in DNA rather than RNA because RNA of adequate quality is not available in many clinical situations while DNA can be readily obtained even from archival samples. IgCap involves three steps: (i) the tumor DNA is first randomly sheared and ligated to adapters that allow their subsequent amplification by PCR; (ii) fragments containing IgH genes are captured on a solid support containing the sequences of interest \[[@R11]\]; and (iii) the captured DNA is amplified by conventional PCR, producing an IgCap library, and the ends of the captured DNA fragments are subjected to massively parallel sequencing.

The sequence information obtained is then processed *in silico* to identify rearranged sequences. Note that IgCap captures *all* fragments containing relevant IgH gene sequences, not simply the rearranged fragments. Moreover, the actual targets of this analysis, i.e., the rearranged loci, are nearly always mutated, both within the exons and at the borders of the rearranged exons. Both these features make the identification of rearrangements challenging, particularly when only a relatively small number of bases from each fragment are determined, as with the Illumina instrument. However, we were able to develop algorithms that could identify rearranged IgH genes on the basis of several features that distinguish them from unrearranged genes. In brief, we developed two algorithms, one that could be used for analysis of one end of a tag and the other for both ends in paired-end reads. The first algorithm (called the "CTGGGG-algorithm) identified "seed" fragments that contained a 6 nt sequence which was identical to, or differed at one position, from a conserved sequence present in all J genes (CTGGGG). The second algorithm (called the "paired-end algorithm"), used paired-end reads to identify two sets of seed fragments. The first set included fragments related to normal V, D or J regions but whose ends represented sequences separated by \>10000 bp in unrearranged DNA and in the expected orientation. The second set included fragments in which one of the two ends was related to normal V regions and the other end included specific sequences within J or D regions. The J-specific sequence was CTGGGCCA, while the D-specific sequences included the middle five bases of each of the D regions. In both algorithms, seed fragments were extended to include larger regions of V, D or J by performing homology searches among the other fragments in the sequenced IgCap library.

To determine the sensitivity of these algorithms for identifying rearranged IgH genes, we tested it on 89 known rearrangements recorded in the IMGT/LIGM-DB database ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We randomly cleaved \~100,00 bases spanning each rearrangement *in silico* to generate a virtual library of overlapping fragments of 100 bp that mimicked the size of the DNA fragments actually used to make IgCap libraries. Each library was then analyzed using the two algorithms. The combination of the alogorithms resulted in the identification of all 89 re-arrangements. No rearrangements were detected in analogous *in silico* libraries constructed from unrearranged IgH loci.

Identification of rearranged IgH genes directly from plasma {#s2_2}
-----------------------------------------------------------

Using the approach described above, we first attempted to directly identify IgH gene rearrangements in DNA purified from plasma in 14 patients in whom no tumor tissue was available (clinical characteristics are described in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). We used an Illumina GA2 sequencer to analyze one end of each tag, employing one lane per patient. We were thereby able to generate 2,673,399 to 18,889,095 tags of high quality from the 14 patients (Table [1](#T1){ref-type="table"}). In ten of the samples, we identified putative rearrangements (Table [2](#T2){ref-type="table"}). We applied the same procedure to the plasma DNA of two individuals without B-cell neoplasia, and did not identify any rearrangements. We then designed primer pairs ([Supplementary Table 3](#SD3){ref-type="supplementary-material"}) that straddled the ten NHL patient rearrangements and used them to PCR-amplify DNA from the same plasma samples. In eight of the ten cases, we identified PCR products of the expected size in the plasma of the appropriate patients but not in DNA from normal individuals (Figure [1](#F1){ref-type="fig"}). The PCR fragments were excised from the gel, cloned, and sequenced. In each case, the sequence was that predicted from the algorithm (with the exception of a single base substitution that could have arisen during cloning, whole genome amplification or clonal progression).

###### Sequencing summary

  Patient ID   Total tags   Bases Sequenced   Tags matched uniquely to human genome   Bases matched to genome   Tags matched to the Ig region   Tags matched to the Ig coding sequences   Bases matched to the Ig region   Average coverage of the Ig region   Target bases with more than 10 reads (number)   Target bases with more than 10 reads (%)
  ------------ ------------ ----------------- --------------------------------------- ------------------------- ------------------------------- ----------------------------------------- -------------------------------- ----------------------------------- ----------------------------------------------- ------------------------------------------
  Patient 1    18,889,095   944,454,750       7,359,299                               367,964,950               214,548                         88,916                                    10,727,400                       251                                 14437                                           61%
  Patient 2    3,183,730    159,186,500       1,109,460                               55,473,000                166,626                         97,334                                    8,331,300                        275                                 13826                                           59%
  Patient 3    11,265,224   563,261,200       6,077,027                               303,851,350               164,494                         78,858                                    8,224,700                        223                                 14373                                           61%
  Patient 4    17,306,516   865,325,800       5,053,458                               252,672,900               320,330                         162,534                                   16,016,500                       459                                 14401                                           61%
  Patient 5    11,149,375   557,468,750       4,385,951                               219,297,550               114,142                         52,816                                    5,707,100                        149                                 13912                                           59%
  Patient 6    4,166,839    208,341,950       2,351,275                               117,563,750               119,952                         59,362                                    5,997,600                        168                                 14588                                           62%
  Patient 7    3,875,106    193,755,300       2,405,508                               120,275,400               125,808                         64,365                                    6,290,400                        182                                 14611                                           62%
  Patient 8    9,741,614    487,080,700       6,221,945                               311,097,250               131,132                         57,886                                    6,556,600                        163                                 14726                                           62%
  Patient 9    2,673,399    133,669,950       1,391,649                               69,582,450                36,284                          19,443                                    1,814,200                        55                                  13541                                           57%
  Patient 10   16,909,387   845,469,350       10,206,055                              510,302,750               156,254                         70,047                                    7,812,700                        198                                 14656                                           62%
  Patient 11   15,218,254   760,912,700       7,460,806                               373,040,300               450,949                         268,217                                   22,547,450                       757                                 15888                                           67%
  Patient 12   9,693,373    484,668,650       5,592,951                               279,647,550               145,140                         64,939                                    7,257,000                        183                                 14526                                           62%
  Patient 13   3,344,057    167,202,850       1,982,627                               99,131,350                53,919                          31,062                                    2,695,950                        88                                  13644                                           58%
  Patient 14   16,818,309   840,915,450       6,464,306                               323,215,300               334,392                         155,854                                   16,719,600                       440                                 14642                                           62%
  Patient 15   22,785,641   1,139,282,050     12,265,838                              613,291,900               830,469                         609,774                                   41,523,450                       1721                                16851                                           95%
  Patient 16   19,547,977   977,398,850       11,370,485                              568,524,250               789,493                         586,682                                   39,474,650                       1656                                16866                                           95%
  Patient 17   21,925,769   1,096,288,450     12,059,079                              602,953,950               701,194                         503,556                                   35,059,700                       1421                                16837                                           95%

###### Rearrangements identified in this study

  Patient ID     Sample type     Rearranged Sequence Identified                                                                                                                                                                                                                                        Rearranged Genes   Validated by PCR\*
  -------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ --------------------
  Patient 1      Plasma          CTGGGTGGATTCTGAACAGCCCCGAGTCACGGTGGGTATAGTGGGAGCCGAGGCCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGAGTCCT                                                                                                                                                                 IGHD1-1:J5         Yes
  Patient 2      Plasma          GCAGACACGGCTGTGTATTACTGTGCGAGACTGGGATCCCCGTATAGCAGCAGCTGGCCCTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTC                                                                                                                                                        IGHV4-30-2:J6      Yes
  Patient 3      Plasma          CCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGAGTGTTGATTATTCTGGGGACACCTTCCATAACCCATCCCTCAAGAGTCGCGTCTCCATATTAATAGACGCGTCTAAAAACGTTTTCTCTCTGAGGTTGACTTTTGTTACCGCCGCGGACACGGCCATATATTATTGTGCGGGACATCCTCATAGTACTGGGTGGTATCAATCTGGGAACTGGTTCGACTCCTGGGGCCAGGGAACCCCGGTCACCGTCTCCTCA   IGHV4-4:J5         Yes
  Patient 4      Plasma          CCGCGGACACGGCCATCTATTACTGTGCGAGAGATAAAGCAGATAAAACATTACGATGGCCCAAGACCTTAAACTGGTTCGACCCCTGGGGCCACGGAACCCTGGTCACC                                                                                                                                                        IGHD4-23:J5        Yes
  Patient 5      Plasma          CCTGTGGACACAGCCACATATTACTGTGCAGCAGTAGAACTAATTGAGGCCGGCATGGAACTTGGCTACTGGGGCCCCCGGGAATCCTGGTCAACGTCTCCTCAGGTGAGTCCTC                                                                                                                                                   IGHV2-5:J5         Yes
  Patient 6      Plasma          TGTCACTGTGGTATTACGATTCTTTGACTGGTTGTTGTCAGCGCGACCCCTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGA                                                                                                                                                                   IGHD3-9:J4         Yes
  Patient 7      Plasma          CCAGGTGTGGTTATTGTCAGGGGGTGCCAGGCCGTGGTAGAGATGGCTACAACTACCAACCACGAGGGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACC                                                                                                                                                           IGHD5-24:J4        Yes
  Patient 8      Plasma          CAGGCCGTGGTAGAGATGGCTACAATCAGGATTGCATGGTCGTCGTTTACGGGGGGTTTTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTC                                                                                                                                                                         IGHD5-24:J4        Yes
  Patient 9      Plasma          TGTGGTATTACTATGATAGTAGTGTGAGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA                                                                                                                                                                                                           IGHD3-22:J5        No
  Patient 10     Plasma          AACCGAGGACACAGCCGTGTATTACTGTACCACAGGGGCGTACTGGGGCCAGGGAACCCT                                                                                                                                                                                                          IGHV3-49:J4        No
  Patient 11     Plasma          \-                                                                                                                                                                                                                                                                    \-                 No
  Patient 12     Plasma          \-                                                                                                                                                                                                                                                                    \-                 No
  Patient 13     Plasma          \-                                                                                                                                                                                                                                                                    \-                 No
  Patient 14     Plasma          \-                                                                                                                                                                                                                                                                    \-                 No
  Patient 15     Primary tumor   TCTGTGACCGCCGCAGACACGGCTGTGTATTTTTGTGCGAGGCAGGTTGCGACGCAGGGGGCCCCCTTTGACTTCTGGGGCCGGGGAACCCTGATCACCGTCTCCTCAGGTGAGTCCT                                                                                                                                                IGHV4-30-2:J4      Yes
  Patient 15     Primary tumor   TGAGGTCTGTGTCACTGTGATATTATGATACTTTGACTGGTTATTTGAGAAAGTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGG                                                                                                                                                                      IGHD3-9:J4         Yes
  Patient 16     Primary tumor   GTACGTGCCATGTTAGGATTTTGATCGAGGAGACAGCACCATGGGTATGGTTTCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGGTGA                                                                                                                                                                        IGHD3-10:J1        Yes
  Patient 16\*   Primary tumor   TTCCAGGTGTGGTTATTGTCAGGCGATGTCAGACTGTGGTGGATATAGTGGCTACGATCCCTCACCTTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGGTAAGATGGCT                                                                                                                                                    IGHD5-12:J3        Yes
  Patient 17     Primary tumor   GTAGGGACAGGAGGATTTTGTGGGGGCTCGAGTCACTGTGAGCATATTGTGGTGGTGATTGCTCCGCTGAATACTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCC                                                                                                                                                     IGHD2-21:J1        Yes
  Patient 17     Primary tumor   TCTTCAAATGAACAACCTGAGAGTCGAGGACACGGCCGTTTATTACTGTACGAGAGAGACAAATTGTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGA                                                                                                                                                       IGHV3-53:J5        Yes

![PCR amplification of Ig rearrangements in plasma\
DNA was purified from either the plasma of patients or from normal cells of an unrelated patient (Con). MW, molecular weight markers, size indicated on left in base pairs (bp).](oncotarget-02-178-g001){#F1}

Identification of rearranged IgH genes in tumors {#s2_3}
------------------------------------------------

Though the results described above were encouraging, we could not definitively identify rearrangements in 6 of the 14 patients. Moreover, the number of IgCap library fragments containing sequences corresponding to the rearranged gene was generally small, ranging from 1 to 11 in those patients in which a rearrangement could be identified. Plasma DNA is certainly not enriched in rearranged fragments, and most IgH gene-containing DNA fragments from plasma are undoubtedly derived from non-tumor tissue. To improve the sensitivity of IgCap, two modifications were made. First and most importantly, we used a portion of the original lymphoma, rather than the plasma, to identify rearrangements, then used plasma to determine whether the rearranged IgH gene could be detected in the circulation. Second, it became possible to sequence both ends of library fragments ("paired-end reads") during the course of this study, and this sequencing approach was employed in the remaining experiments.

This modified strategy was applied to DNA isolated from the involved lymph nodes of three NHL patients (clinical information in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). From a single lane of an Illumina GAIIx sequencer, we recovered 20 million tags of high sequence quality, 6-7% of which contained homology to V, D, or J regions (Table [1](#T1){ref-type="table"}). In each of the three patients, IgCap identified two rearrangements that were represented by more than 8 tags (Table [2](#T2){ref-type="table"}). One of the two rearrangements in each patient was presumably derived from the maternal allele and the other from the paternal allele. Importantly, the number of IgCap library fragments containing sequences that bridged the rearrangement was more than one in each case, ranging from 8 to 36. In two of the six rearrangements, we could identify both VD and DJ junctions. In the remaining 4, we could only identify the DJ junction. We did not determine whether this was due to technical vs. biologic reasons; it is well-known that incomplete rearrangements, in which D is fused to J but V is not fused to D, occur in neoplastic B-cells.\[[@R12]\]

PCR primers that straddled the six rearrangements were used to amplify DNA from the three tumors. In each case, PCR products of the expected size were found in the tumors of the appropriate patients but not in germ-line DNA from normal individuals (Figure [2](#F2){ref-type="fig"}). The PCR fragments were excised from the gel, cloned, and sequenced. In each case, the sequence was that predicted from the IgCap data.

![PCR amplification of Ig rearrangements in tumors and plasma\
Two Ig rearrangements are shown for each patient sample. DNA was purified from either from the tumor and plasma of patients or from normal cells of an unrelated patient (Con). MW, molecular weight markers, size indicated on left in base pairs (bp).](oncotarget-02-178-g002){#F2}

We next attempted to determine whether the rearranged fragments could be identified in the plasma of these three patients. In all cases, both rearranged fragments were evident and could be detected in as little as 30 ul of plasma (Figure [2](#F2){ref-type="fig"}). The PCR fragments from plasma were cloned and found to be identical in sequence to those of the corresponding patients\' tumors. The number of rearranged fragments was determined by digital PCR and found to vary from 30 to 100 fragments per ml of plasma. These rearrangements were not detected in DNA from circulating cells from the same patients, even when the DNA from as many as 1 million circulating cells were assessed. . These results are consistent with the idea that lymphoma cells are rare in the circulation and that the rearranged DNA is released from the tumors in situ rather than derived from circulating lymphoma cells.

DISCUSSION {#s3}
==========

The results described above show that rearranged IgH genes can be routinely identified in NHL tumors, that the rearranged genes are present in the circulation at detectable levels, and that the circulating DNA is more abundant than circulating lymphoma cells. Moreover, the IgCap approach is powerful enough to identify some patients\' rearrangements directly from plasma if no tumor biopsy is available. These results set the stage for clinical implementation of this type of biomarker to follow the course of NHL patients following therapy.

The clonal assessment of rearrangements in immunoglobulin or T cell receptor genes has a long history.\[[@R10]\] Initially, Southern blotting was the gold standard for this type of analysis, but required large amounts of high quality genomic DNA and lacked the sensitivity required for many types of diagnostic assays. Southern blotting was replaced with PCR-based assays, which have many advantages. Primer sets facilitating multiplex PCR assays have been painstakingly designed and shown to detect up to 74% DLBCL and 96% FL.\[[@R13]\] Massively parallel sequencing of PCR products derived from such primer sets has recently been used to identify VDJ rearrangements in Ig or T-cell receptor genes. \[[@R14]-[@R16]\] The massively parallel sequencing approach used herein, in which VDJ genes are captured rather than amplified using Ig-specific primers, represents another means towards the identification of clonal rearrangements and their use as biomarkers. Though more complex than the direct PCR approach, it has the advantage of being less biased; in theory, it should detect 100% of rearranged fragments from lymphomatous tissues. Additionally, it can be applied to degraded DNA samples such as those from paraffin-embedded material or plasma. Degraded DNA cannot efficiently be amplified with conventionally used primer sets because the product size is larger than the size of the DNA.

We used two algorithms to identify rearranged Igs. The CTGGGG-based algorithm detects all typical rearranged Igs. However, this algorithm can fail to detect uncommon Ig rearrangements such as those involving only V and D or those involving J region deletions. The paired-end algorithm is complementary. It has the capacity to pick out any rearrangement involving the IgH locus, including Ig rearrangements as well as translocations such as t(8;14)(q24;q32) in Burkitt lymphoma and t(11;14)(q13;q32) in mantle cell lymphoma.

As with all biomarkers, the approach described here has limitations. Its major conceptual limitation revolves around marker stability: a relapsed lymphoma may have undergone clonal divergence so that its rearrangement would be undetectable upon PCR with the primers used to validate the original tumor.\[[@R17]\] It was therefore comforting that in each of the three NHL tumor samples evaluated in this study, two distinct rearrangements were identified, and both could be identified in the plasma of each patient. The availability of two independent markers reduces the probability of a false negative during follow-up. Because the exact sequence of the rearrangement is determined with our approach, two sets of primers for each rearrangement could be employed, thereby further minimizing the potential impact of clonal evolution within the rearranged loci.

Enthusiasm has been growing for risk-adapted therapy in the treatment of diffuse large B cell lymphoma. Mid cycle FDG PET has been used to guide decisions on switching chemotherapy regimens and to select patients for high dose consolidation.\[[@R18]\],\[[@R19]\] However, standardized interpretation of PET imaging still presents obstacles, as recently noted in an ongoing cooperative group trial.\[[@R20]\] The plasma-based approach described here represents an alternative and perhaps complementary approach to tumor assessment. Another important issue to be addressed in the future is the sensitivity of the method. In this work, we have only evaluated patients with clinically apparent disease. It may be more difficult to detect rearranged IgH genes in the plasma of patients with minimal residual disease following therapy. However, we were encouraged by the fact that rearrangements can be detected in as little as 30 ul of plasma in the three patients whose levels were quantified. This suggests that disease burdens amounting to only 1% of those of the studied patients could be readily detected in 3 ml of plasma, assuming the relationship between disease burden and plasma DNA is linear.

Do the rearrangements detected with IgCap represent those occurring in the tumor cells? In the three cases in which the rearrangements were identified in the tumor, there can be little doubt of this, as the number of IgCap library fragments corresponding to the major rearrangement outnumbered any other putative rearrangements in the sample by more than a hundred-fold. In the cases in which only plasma DNA was available, it is theoretically possible that the identified rearrangements arose from normal B-cells. Two observations argue against this possibility. First, we have attempted the IgCap strategy on two samples of plasma from patients without B-cell neoplasms and have not identified any rearranged fragments in IgCap libraries from them. Second, there were two patients in whom a plasma sample taken during complete remission was available, and the rearrangements could not be identified in these either (through PCR with the rearrangement-specific primers). Regardless, it is clearly optimal to identify the rearranged biomarker by employing the IgCap strategy on DNA from lymphomas, rather than from plasma, whenever the former is available. The biomarker can then be easily applied to plasma using PCR, as described above.

In sum, IgCap is an advanced, personalized medicine approach that provides exciting research opportunities and offers the potential for clinical application. The basic idea of IgCap could be applied to other diseases, including those with an autoimmune or allergic basis, to define the number and nature of Ig rearrangements in clinical samples. With minor modifications, it might also be applied to the evaluation of T-cells.

MATERIALS AND METHODS {#s4}
=====================

Samples {#s4_1}
-------

All samples in this study were obtained from patients under an Institutional Review Board protocol.

DNA purification {#s4_2}
----------------

DNA was extracted from 1000 μL of plasma with a QIAamp Circulating Nucleic Acid kit following the manufacturer\'s instructions. (QIAGEN; Valencia, CA). DNA was extracted from tumor tissues and normal cells using a Qiagen AllPrep kit following the manufacturer\'s protocol.

Illumina library preparation {#s4_3}
----------------------------

Tumor genomic DNA libraries were prepared following Illumina\'s (Illumina, San Diego, CA) protocol with the following modifications. (1) Three micrograms (μg) of genomic DNA in 100 microliter (μl) of TE was fragmented in a Covaris sonicator (Covaris, Woburn, MA) to a size of 100-500bp. DNA was purified with a PCR purification kit (Cat \# 28104, Qiagen, Valencia, CA) and eluted in 35μl of elution buffer included in the kit. (2) Purified, fragmented DNA was mixed with 40 μl of H~2~O, 10 μl of 10xT4 ligase buffer with 10mM ATP, 4 μl of 10mM dNTP, 5 μl of T4 DNA polymerase, 1 μl of Klenow Polymerase, and 5 μl of T4 polynucleotide Kinase. All reagents used for this step and those described below were from New England Biolabs (NEB, Ipswich, MA) unless otherwise specified. The 100μl end-repair mixture was incubated at 20°C for 30 min, purified by a PCR purification kit (Cat \# 28104, Qiagen) and eluted with 32μl of elution buffer (EB). (3) To A-tail, all 32 μl of end-repaired DNA was mixed with 5 μl of 10xBuffer (NEB buffer 2), 10 μl of 1mM dATP and 3 μl of Klenow (exo-). The 50 μl mixture was incubated at 37°C for 30 min before DNA was purified with a MinElute PCR purification kit (Cat \# 28004, Qiagen). Purified DNA was eluted with 12.5 μl of 70°C EB. (4) For adaptor ligation, 10 μl of A-tailed DNA was mixed with 10 μl of adapters (Illumina), 25 μl of 2x Rapid Lgase buffer and 5 μl of Rapid Ligase. The ligation mixture was incubated at room temperature (RT) for 15 min. (5) To purify adapter- ligated DNA, 50 μl of ligation mixture from step (4) was mixed with 200 μl of NT buffer from NucleoSpin Extract II kit (cat\# 636972, Clontech, Mountain View, CA) and loaded into a NucleoSpin column. The column was centrifuged at 13,000 g in a desktop centrifuge for 1 min, washed once with 600 μl of wash buffer (NT3 from Clontech), and centrifuged again for 2 min to dry completely. DNA was eluted in 50μl elution buffer included in the kit. (6) To obtain an amplified library, ten PCRs of 25 μl each were set up, each including 12 μl of H~2~O, 5 μl of 5 x Phusion HF buffer, 0.5 μl of 10 mM dNTP, 1.25 μl of DMSO, 0.5 μl of Illumina PE primer \#1, 0.5 μl of Illumina PE primer \#2, 0.25 μl of Hotstart Phusion polymerase, and 5 μl of the DNA from step (5). The PCR program used was: 98°C 1 minute; 6 cycles of 98°C for 20 seconds, 65°C for 30 seconds, 72°C for 30 seconds; and 72°C for 5 min. To purify the PCR product, 250 μl PCR mixture (from the ten PCR reactions) was mixed with 500 μl NT buffer from NucleoSpin Extract II kit and purified as described in step (5). Library DNA was eluted with elution buffer pre-heated to 70°C and the DNA concentration was estimated by absorption at 260 nm.

IgCap capture {#s4_5}
-------------

The targeted capture region included V-gene exons plus the first 36 bp of the downstream introns, six J-gene exons plus the first 36 bp of the upstream introns, and all the D-gene exons. We obtained these regions through PCR of normal genomic DNA using the primers described in [Supplementary Table 4](#SD4){ref-type="supplementary-material"} or custom synthesized probes and then used a strategy based on that described in \[[@R11]\] to capture the IgH genome. PCR using these primers was performed using the reaction conditions specified previously.\[[@R21]\]

Confirmation of IgH rearrangements in tumor and plasma samples {#s4_6}
--------------------------------------------------------------

The full V-D-J or D-J joint region sequence and 40 bp from either side of the joint were used for primer design. The PCR mixture (50 μl) contained various amounts of template DNA, 0.2 μM of forward-reverse primer mixture, 2.5 mM of MgCl2, 100 μM of dNTPs, and 0.5 units of Invitrogen Taq polymerase. PCR was performed as follows: 96°C for 4 min; 45 cycles of 96°C for 10 s, 59°C for 10 s, and 72°C for 30 s. The primers used for PCR are listed in [Supplementary table 3](#SD3){ref-type="supplementary-material"}. PCR products were gel purified with QIAquick *Gel Extraction Kit (*QIAGEN; Valencia, CA*) and* cloned with a TA clone kit (Promega, Madison, WI, USA) according to the manufacture\'s protocols. Plasmid DNA was evaluated by Sanger sequencing. Digital PCR was performed as described before.\[[@R22]\]
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